FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals ’ DP1038 for the Treatment of Acromegaly

San Diego, Calif., January 30, 2018 – Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announces that the U.S. Food and Drug Administration (FDA) has granted orphan...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials